Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 1/20 | 0.38 |
| ▸ | XIAP | P98170 | 9/20 | 0.38 |
| ▸ | F2 | P00734 | 5/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.34 |
| ▸ | F10 | P00742 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 3/20 | 0.34 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10247714 | 0.93 | CASP3 (0.40) | NPY1RXIAPF2CYP3A4F10 | |
| SCHEMBL10199338 | 0.93 | CASP3 (0.40) | NPY1RXIAPF2CYP3A4F10 | |
| SCHEMBL10199449 | 0.83 | F2 (0.46) | XIAPF2CYP3A4F10CASP1 | |
| SCHEMBL10247946 | 0.83 | F2 (0.46) | XIAPF2CYP3A4F10CASP1 | |
| SCHEMBL644702 | 0.80 | CASP1 (0.47) | XIAPCYP3A4CASP1 | |
| SCHEMBL10249823 | 0.80 | CASP1 (0.47) | XIAPCYP3A4CASP1 | |
| SCHEMBL644704 | 0.80 | CASP1 (0.47) | XIAPCYP3A4CASP1 | |
| SCHEMBL10199324 | 0.78 | XIAP (0.46) | XIAPCYP3A4CASP1 | |
| SCHEMBL10249657 | 0.78 | XIAP (0.46) | XIAPCYP3A4CASP1 | |
| SCHEMBL10201206 | 0.77 | XIAP (0.42) | XIAPCYP3A4CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119631-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110178069-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178069-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1A, IFNAR1, IL1B | NPY1R 3376/4885XIAP 257/4885F2 1160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.